These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33287156)

  • 1. A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results.
    Sessa M; Cavazzini F; Cavallari M; Rigolin GM; Cuneo A
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33287156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic complexity of multiple myeloma and its clinical implications.
    Manier S; Salem KZ; Park J; Landau DA; Getz G; Ghobrial IM
    Nat Rev Clin Oncol; 2017 Feb; 14(2):100-113. PubMed ID: 27531699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Myeloma Genomics - A Concise Review.
    Castaneda O; Baz R
    Acta Med Acad; 2019 Apr; 48(1):57-67. PubMed ID: 31264433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
    J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
    Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
    Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
    Kjeldsen E
    Cancer Genomics Proteomics; 2016; 13(2):91-127. PubMed ID: 26912802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Clinical Application of Genomics in Multiple Myeloma.
    Soekojo CY; de Mel S; Ooi M; Yan B; Chng WJ
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic analysis of high-risk smoldering multiple myeloma.
    López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
    Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
    D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
    J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.
    Awada H; Thapa B; Awada H; Dong J; Gurnari C; Hari P; Dhakal B
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
    Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
    Bolli N; Biancon G; Moarii M; Gimondi S; Li Y; de Philippis C; Maura F; Sathiaseelan V; Tai YT; Mudie L; O'Meara S; Raine K; Teague JW; Butler AP; Carniti C; Gerstung M; Bagratuni T; Kastritis E; Dimopoulos M; Corradini P; Anderson KC; Moreau P; Minvielle S; Campbell PJ; Papaemmanuil E; Avet-Loiseau H; Munshi NC
    Leukemia; 2018 Dec; 32(12):2604-2616. PubMed ID: 29789651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of DNA Repair in Genomic Instability of Multiple Myeloma.
    Ali JYH; Fitieh AM; Ismail IH
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
    Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies F; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan G
    Leukemia; 2019 Jan; 33(1):159-170. PubMed ID: 29967379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma: current perspectives.
    Slovak ML
    Clin Lab Med; 2011 Dec; 31(4):699-724, x. PubMed ID: 22118745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways.
    Ortiz-Estévez M; Towfic F; Flynt E; Stong N; Jang IS; Wang K; Trotter MWB; Thakurta A
    BMC Med Genomics; 2021 Dec; 14(1):295. PubMed ID: 34922559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma genetics and genomics: practice implications and future directions.
    Faiman B
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiple myeloma from the pathologist's perspective].
    Vogelsberg A; Schürch CM; Fend F
    Radiologe; 2022 Jan; 62(1):12-19. PubMed ID: 34661686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.